Early CD4+ T cell responses are associated with subsequent CD8+ T cell responses to an rAd5-based prophylactic prime-boost HIV vaccine strategy

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Lhomme, Edouard ^a,b,c,d,e   Richert, Laura ^a,b,c,d,e   Moodie, Zoe ^f,g   Pasin, Chloé ^a,b,d   Kalams, Spyros A ^h   Morgan, Cecilia ^f,g   Self, Steve ^f,g   De Rosa, Stephen C ^f,g   Thiébaut, Rodolphe ^a,b,c,d,e  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d INRIA SISTM   (France)

^e Vaccine Research Institute   (France)

^f Fred Hutchinson Cancer Research Center   (United States)

^g HIV Vaccine Trials Network   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; RECOMBINANT ADENOVIRAL SEROTYPE 5 VACCINE; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT DNA; VIRUS ANTIBODY;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION; ADENOVIRIDAE; ADOLESCENT; CLINICAL TRIAL; GENE VECTOR; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PROCEDURES; SECONDARY IMMUNIZATION; YOUNG ADULT;

ADENOVIRIDAE; ADOLESCENT; ADULT; AIDS VACCINES; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA, RECOMBINANT; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; MIDDLE AGED; VACCINATION; VACCINES, DNA; YOUNG ADULT;

EID: 84965099757     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152952     Document Type: Article

References (34)

1. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 868-71. PMID: 6189183
2. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: 2013.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20. doi: 10.1056/NEJMoa0908492 PMID: 19843557
4. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372(9653): 1881-93. doi: 10.1016/S0140-6736(08)61591-3 PMID: 19012954
5. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191(5): 654-65. PMID: 15688278
6. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11(7): 507-15. doi: 10.1016/S1473-3099(11)70098-6 PMID: 21570355
7. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N Engl J Med 2013; 369(22): 2083-92. doi: 10.1056/NEJMoa1310566 PMID: 24099601
8. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194(12): 1661-71. PMID: 17109337
9. Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011; 203(7): 969-75. doi: 10.1093/infdis/jiq152 PMID: 21402548
10. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vC1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012; 12 (7): 531-7. doi: 10.1016/S1473-3099(12)70088-9 PMID: 22652344
11. Bevan MJ. Helping the CD8+ T-cell response. Nat Rev Immunol 2004; 4(8): 595-602. PMID: 15286726
12. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8(4): 247-58. doi: 10.1038/nri2274 PMID: 18323851
13. Richert L, Lhomme E, Fagard C, Lévy Y, Chêne G, Thiébaut R. Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccin Immunother 2015; 11(4): 1022-9. doi: 10.1080/21645515.2015.1011974 PMID: 25751670
14. Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. J Infect Dis 2010; 202: S302-8. doi: 10.1086/655652 PMID: 20846037
15. Ling Munier CM, Kelleher AD, Kent SJ, De Rose R. The role of T cell immunity in HIV-1 infection. Curr Opin Virol 2013; 3(4): 438-46. doi: 10.1016/j.coviro.2013.05.009 PMID: 23747036
16. Perreau M, Levy Y, Pantaleo G. Immune response to HIV. Curr Opin HIV AIDS 2013; 8(4): 333-40. doi: 10.1097/COH.0b013e328361faf4 PMID: 23743723
17. De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, et al. HIV-DNA priming alters T-cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol 2011; 187(6): 3391-401. doi: 10.4049/jimmunol.1101421 PMID: 21844392
18. Horton H, Thomas E, Stucky J, Frank I, Moodie Z, Huang Y, et al. Optimization and Validation of an 8-Color Intracellular Cytokine Staining (ICS) Assay to Quantify Antigen-Specific T Cells Induced by Vaccination. J Immunol Methods 2007; 323(1): 39-54. PMID: 17451739
19. Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, et al; NIAID HIV Vaccine Trials Network. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25(3):510-8. PMID: 17049679
20. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity 2013; 38: 373-83. doi: 10.1016/j.immuni.2012.10.021 PMID: 23395677
21. Benjamini Y, Hochberg Y. On the Adaptive Control of the False Discovery Rate in Multiple Testing with Independent Statistics. J Educ Behav Stat 2000; 25: 60-83.
22. Jacqmin-Gadda H, Sibillot S, Proust C, Molina JM, Thiébaut R. Robustness of the linear mixed model to misspecified error distribution. Computational Statistics and Data Analysis 2007; 51: 5142-54.
23. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New-York, Springer; 2000.
24. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
25. Boyman O, Cho JH, Sprent J. The role of interleukin-2 in memory CD8 cell differentiation. Adv Exp Med Biol. 2010; 684:28-41. PMID: 20795538
26. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012; 12(3):180-90. doi: 10.1038/nri3156 PMID: 22343569
27. Lai YP, Lin CC, Liao WJ, Tang CY, Chen SC. CD4+ T cell-derived IL-2 signals during early priming advances primary CD8+ T cell responses. PLoS One 2009; 4(11): e7766. doi: 10.1371/journal.pone.0007766 PMID: 19901991
28. García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 2011; 29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098 PMID: 21907749
29. Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, et al. NIAID HIV Vaccine Trials Network. Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults. PLoS One 2012; 7(1):e29231. doi: 10.1371/journal.pone.0029231 PMID: 22242162
30. Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, et al. Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. Clin Vaccine Immunol 2014; 21(11):1589-99. doi: 10.1128/CVI.00450-14 PMID: 25253665
31. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, et al. Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate. PLoS One 2010; 5(11):e13983. doi: 10.1371/journal.pone.0013983 PMID: 21085591
32. Agnellini P, Wiesel M, Schwarz K, Wolint P, Bachmann MF, Oxenius A. Kinetic and mechanistic requirements for helping CD8 T cells. J Immunol 2008; 180(3): 1517-25. PMID: 18209047
33. Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DC, et al. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Vaccine 2015; 33(20): 2347-53. doi: 10.1016/j.vaccine.2015.03.036 PMID: 25820067
34. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208(5): 818-29. doi: 10.1093/infdis/jit236 PMID: 23840043